Drug
Aln Agt01 Rvr
Aln Agt01 Rvr: highest development phase Phase 2, developed by Alnylam Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Alnylam Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALN-AGT01 RVR NCT07553442 | Phase 2 | Hypertension |
Latest
No recent events.
Follow Aln Agt01 Rvr on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.